Gut metagenome‐derived signature predicts hepatic decompensation and mortality in NAFLD‐related cirrhosis
Suzanne R. Sharpton(University of California San Diego), Rohit Loomba(University of California San Diego), Ruth T. Yu(Peking University), Annette R. Atkins(Salk Institute for Biological Studies), Chenjingyi Wang(University of British Columbia), Ronald M. Evans(University of California San Diego), Michael Downes(Salk Institute for Biological Studies), Egbert Madamba(University of California San Diego), Tao Huan(University of British Columbia Hospital), Tae Gyu Oh(University of Oklahoma Health Sciences Center)
Cited by 11
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k